Certolizumab pegol

被引：142

作者：

Goel, Niti ^{[1
]}

Stephens, Sue ^{[2
]}

机构：

[1] UCB Inc, Global Projects & Dev, Dis Area Immunol, ASBMR,ACP,AC Rheumatol, Smyrna, GA USA

[2] UCB Celltech, Nonclin Dev, Slough, Berks, England

来源：

MABS | 2010年 / 2卷 / 02期

关键词：

certolizumab pegol; rheumatoid arthritis; Crohn disease; TNF alpha; PEGylated; methotrexate; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; ANTIBODY FRAGMENTS; METHOTREXATE; INFLIXIMAB; THERAPY; CDP870;

D O I：

10.4161/mabs.2.2.11271

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Certolizumab pegol (Cimzia*) is currently the only PEGylated anti-TNF alpha biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.

引用

页码：137 / 147

页数：11

共 37 条

[1]

[Anonymous], 2009, Drug Eval, V3, P253, DOI 10.2217/ijr.09.12

[2] Therapeutic antibody fragments with prolonged in vivo half-lives [J].

Chapman, AP ;

Antoniw, P ;

Spitali, M ;

West, S ;

Stephens, S ;

King, DJ .

NATURE BIOTECHNOLOGY, 1999, 17 (08) :780-783

[3] PEGylated antibodies and antibody fragments for improved therapy: a review [J].

Chapman, AP .

ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) :531-545

[4]

*CLIN STUD, CLIN STUD SUMM

[5] Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol:: first results of the music clinical trial [J].

Colombel, Jean-Frederic ;

Hebuterne, Xavier .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 :S432-S432

[6]

FELFMANN M, 1996, ANNU REV IMMUNOL, V14, P397

[7] Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study [J].

Fleischmann, R. ;

Vencovsky, J. ;

van Vollenhoven, R. F. ;

Borenstein, D. ;

Box, J. ;

Coteur, G. ;

Goel, N. ;

Brezinschek, H-P ;

Innes, A. ;

Strand, V. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :805-811

[8]

Fleischmann Roy, 2003, Mol Interv, V3, P310, DOI 10.1124/mi.3.6.310

[9]

Gramlick A, 2006, GASTROENTEROLOGY, V130, pA697

[10] Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis -: Results from a large UK national cohort study [J].

Hyrich, Kimme L. ;

Lunt, Mark ;

Watson, Kath D. ;

Symmons, Deborah P. M. ;

Silman, Alan J. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :13-20

← 1 2 3 4 →